What is the appropriate oral dose of cefdinir for a patient weighing 43.09 kg?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 4, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Cefdinir Oral Dose for 43.09 kg Patient

For a patient weighing 43.09 kg, the appropriate cefdinir dose is 600 mg per day, administered as either 300 mg twice daily or 600 mg once daily, depending on the indication. 1

Weight-Based Dosing

According to the FDA-approved dosing, pediatric patients weighing ≥43 kg should receive the maximum daily dose of 600 mg 1. Your patient at 43.09 kg falls into this category.

Dosing Options by Indication

For most infections (otitis media, sinusitis, pharyngitis/tonsillitis):

  • 300 mg every 12 hours, OR
  • 600 mg once daily 1

For uncomplicated skin and skin structure infections:

  • 300 mg every 12 hours only (once-daily dosing has not been studied for skin infections) 1

Practical Administration

Using the 250 mg/5 mL suspension formulation:

  • Twice daily dosing: 6 mL every 12 hours
  • Once daily dosing: 12 mL once daily (except for skin infections) 1

The medication may be administered without regard to meals, though taking it with food may improve gastrointestinal tolerability 1.

Duration of Treatment

  • Acute bacterial otitis media: 5-10 days
  • Acute maxillary sinusitis: 10 days
  • Pharyngitis/tonsillitis: 5-10 days
  • Uncomplicated skin infections: 10 days 1

Important Considerations

Renal function: If creatinine clearance is <30 mL/min/1.73 m², reduce dose to 7 mg/kg (approximately 300 mg) once daily 1.

Clinical context matters: While the FDA label provides clear dosing for patients ≥43 kg, note that cefdinir is listed only as an alternative agent for certain infections. For example, in community-acquired pneumonia guidelines, cefdinir appears as an alternative for β-lactamase producing Haemophilus influenzae 2, not as first-line therapy.

Bioavailability concerns: Be aware that cefdinir has relatively low oral bioavailability (16-25%) 1, which is particularly relevant if considering it for urinary tract infections where recent evidence suggests higher treatment failure rates compared to cephalexin 3.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.